Indiana Clinical Trials Report — April 2026

For Hoosiers considering participation in clinical research, April 2026 brings a critical reminder: time is running out for many studies. Across Indiana, a significant number of trials are nearing their enrollment deadlines, with 95 opportunities expected to close within the next 90 days. This urgency extends to healthy volunteers, as 12 of these rapidly concluding studies are still actively seeking participants without specific health conditions. If you've been contemplating contributing to medical advancements, now is a crucial moment to explore these options before they are no longer available.

Patients managing specific health challenges also face impending deadlines to join research. Conditions with trials closing soon include:

• Alzheimer disease
• Advanced solid tumor
• Mild cognitive impairment
• Stage IV lung cancer AJCC V8
• Neuroblastoma
• Cystic fibrosis (CF)
• Heart failure
• Adult surgical procedures

April's Research Landscape: A Closer Look at New Opportunities

This month, Indiana saw the launch of 5 new clinical trials, a notable decrease compared to the 20 trials that opened in March 2026. Despite this dip in new openings, the state continues to offer valuable research opportunities, with a total of 1,204 clinical trials currently recruiting across 61 cities and 766 research sites statewide.

Among the new studies, several stand out due to their sponsors and the conditions they address:

• Eli Lilly and Company is sponsoring NCT07533019, a Phase 2 study evaluating LY4005130 in adult participants with non-segmental vitiligo (NSV). This trial aims to enroll 60 participants to assess the tolerability and side effects of the investigational drug administered intravenously.
• Incyte Corporation is launching NCT07522073, a Phase 3 study investigating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants to evaluate the efficacy and safety of the combined treatment.
• Memorial Sloan Kettering Cancer Center is leading NCT07507643, a Phase 3 study on the use of methylprednisolone in people undergoing liver surgery. This trial, designed for 750 participants, aims to determine if receiving methylprednisolone before surgery can reduce side effects like infections and shorten hospital stays.
• A registry analysis, NCT07530991, sponsored by Chris Jaynes, is evaluating outcomes associated with normothermic machine perfusion (NMP) of deceased donor kidneys using existing transplant data. This study plans to include 3,500 participants.

The new trials this month are exploring a range of conditions, including:

• Autism
• Hepatectomy
• Non-segmental vitiligo (NSV)
• Normothermic machine perfusion (NMP) of deceased donor kidneys
• Solid tumors
• Vitiligo

The majority of these new opportunities are drug trials, accounting for 3 of the 5 new studies, with one behavioral trial also opening. Industry sponsors, including Eli Lilly and Company and Incyte Corporation, are driving 4 of these new research efforts, demonstrating a strong pharmaceutical presence in the state's research landscape.

Geographic Accessibility and Diverse Participation

This month's new trials are primarily concentrated in Indiana's larger urban centers, with 3 of the new studies opening in Indianapolis. Other cities seeing new research opportunities include Bloomington, Muncie, and West Lafayette. While new trial openings this month show a metropolitan focus, the overall research landscape remains broadly accessible across Indiana, with recruiting trials found in 61 cities.

Participation in clinical trials is open to a wide array of individuals. Of the 5 new trials launched this month, 4 are designed to include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is open to children. There are no new trials this month specifically for female-only or male-only participants.

For individuals without a specific medical condition, opportunities to contribute are still available. While none of the 5 new trials this month are seeking healthy volunteers, a total of 125 trials across Indiana are currently recruiting healthy participants. These studies play a vital role in establishing baseline data and testing new interventions in healthy populations.

As we look ahead, the continued enrollment in these significant Phase 2 and 3 trials, alongside the ongoing efforts in the state's many research sites, will further advance medical knowledge and offer new options for patients and healthy volunteers across Indiana.